bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 6 from Apigenin Sensitizes Colon Cancer Cells to Antitumor Activity of ABT-263
Authors: Shao Huanjie , Jing Kai , Mahmoud Esraa , Huang Haihong , Fang Xianjun , Yu Chunrong
Published: April 2023

PDF - 427KB, Supplementary Figure S6. Apigenin downregulated Mcl-1 expression at mRNA level.
Supplementary Figure S2 from Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Authors: Sumi Hiroyuki , Yabuki Masato , Iwai Kenichi , Morimoto Megumi , Hibino Ryosuke , Inazuka Masakazu , Hashimoto Kentaro , Kosugi Yohei , Aoyama Kazunobu , Yamamoto Shunsuke , Yoshimatsu Mie , Yamasaki Hideki , Tozawa Ryuichi , Ishikawa Tomoyasu , Yoshida Sei
Published: April 2023

PDF file - 332KB, Proteasomal degradation of cIAP-1 and activation of NF-�B pathway by T-3256336 treatment
Supplementary Figure Legends from Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Authors: Sumi Hiroyuki , Yabuki Masato , Iwai Kenichi , Morimoto Megumi , Hibino Ryosuke , Inazuka Masakazu , Hashimoto Kentaro , Kosugi Yohei , Aoyama Kazunobu , Yamamoto Shunsuke , Yoshimatsu Mie , Yamasaki Hideki , Tozawa Ryuichi , Ishikawa Tomoyasu , Yoshida Sei
Published: April 2023

PDF file - 72KB
Supplementary Methods from Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and γH2AX
Authors: Cornelissen Bart , Waller Andrew , Able Sarah , Vallis Katherine A.
Published: April 2023

PDF - 108KB, Supplementary methods.
Supplementary Figure 3 from New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Authors: Wei Yinxiang , Ma Yuanfang , Zhao Qing , Ren Zhiguang , Li Yan , Hou Tingjun , Peng Hui
Published: April 2023

PDF file, 114KB, Effect of sorafenib on ABCG2 expression level in the MCF/MX cells.
Supplementary Figure 6 from Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation
Authors: Kim Sun Mi , Kwon Oh-Joon , Hong Yun Kyoung , Kim Joo Hang , Solca Flavio , Ha Sang-Jun , Soo Ross A. , Christensen James G. , Lee Ji Hyun , Cho Byoung Chul
Published: April 2023

PDF file, 20K, Effect of Src inhibitor on afatinib-induced STAT3 activation.
Supplementary Figure 5 from CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma
Authors: Salas Fragomeni Roberto A. , Chung Hye Won , Landesman Yosef , Senapedis William , Saint-Martin Jean-Richard , Tsao Hensin , Flaherty Keith T. , Shacham Sharon , Kauffman Michael , Cusack James C.
Published: April 2023

Supplementary Figure 5 - PDF file 894K, CRM1 inhibition leads to delayed tumor growth independent of BRAF or NRAS status in melanoma xenograft models
Supplementary Methods from Cancer-Associated CD43 Glycoforms as Target of Immunotherapy
Authors: Tuccillo Franca Maria , Palmieri Camillo , Fiume Giuseppe , de Laurentiis Annamaria , Schiavone Marco , Falcone Cristina , Iaccino Enrico , Galandrini Ricciarda , Capuano Cristina , Santoni Angela , D'Armiento Francesco Paolo , Arra Claudio , Barbieri Antonio , Dal Piaz Fabrizio , Venzon David , Bonelli Patrizia , Buonaguro Franco Maria , Scala Iris , Mallardo Massimo , Quinto Ileana , Scala Giuseppe
Published: April 2023

PDF file - 37K
Supplementary Figures 1 - 7 from Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Authors: Wang Yu , Yu Qi , He Xin , Romigh Todd , Altemus Jessica , Eng Charis
Published: April 2023

PDF file - 1622K, Figure S1.Combinaion of DHT and NVP-BEZ235 induced synergistic effect of growth inhibition in MCF cells growth. Figure S2. Combination of DHT and NVP-BEZ235 exposure affects expression of markers of epithelial to mesenchymal transitions (EMT) in MCF-7 cells. Figure S3. DHT did not inhibit AR-negative breast cancer cell growth. HCC1395 (AR-/ER+) and MDA-MB-231 (AR-/ER-) cells were treated with control, DHT, NVP-BEZ235 or DHT/BEZ235 combination for 5 days. Figure S4. Combination of DHT and NVP-BEZ235 achieved better therapeutic effects in breast cancer xenografts compared to either single agent. Figure S5. Tumors from mouse MCF-7 xenografts were dissected and subjected to immunohistochemistry for the shown proteins. Figure S6. DHT suppressed low level NVP-BEZ235-induced MYC expression and AKT phosphorylation in breast cancer. Figure S7. DHT decreased the known side effects of NVP-BEZ235 treatment.
Supplementary Figures 1 - 2, Table 1 from Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Authors: Keegan Kathleen , Li Cong , Li Zhihong , Ma Ji , Ragains Mark , Coberly Suzanne , Hollenback David , Eksterowicz John , Liang Lingming , Weidner Margaret , Huard Justin , Wang Xianghong , Alba Grace , Orf Jessica , Lo Mei-Chu , Zhao Sharon , Ngo Rachel , Chen Ada , Liu Lily , Carlson Timothy , Quéva Christophe , McGee Lawrence R. , Medina Julio , Kamb Alexander , Wickramasinghe Dineli , Dai Kang
Published: April 2023

PDF file - 132KB, Figure S1. Plasma concentration-time profiles of AMG 925 in rat, dog, and cynomolgus monkey following oral administration. Figure S2. Inhibition of STAT5 and Rb phosphorylation by AMG 925 in MOLM13-Luc tumor cells in bone marrow. Table S1. Selectivity profile of AMG 925 (Kd for kinases with POC < 20 at 1 microM in KenomScan).
Supplementary Figures 1 through 6 from Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Authors: Golfier Sven , Kopitz Charlotte , Kahnert Antje , Heisler Iring , Schatz Christoph A. , Stelte-Ludwig Beatrix , Mayer-Bartschmid Anke , Unterschemmann Kerstin , Bruder Sandra , Linden Lars , Harrenga Axel , Hauff Peter , Scholle Frank-Detlef , Müller-Tiemann Beate , Kreft Bertolt , Ziegelbauer Karl
Published: April 2023

PDF - 3895K, Supplementary Figure S1. Immunohistochemical detection of mesothelin expression in FFPE tissues of human primary ovarian cancer, pancreatic cancer, and mesothelioma. Supplementary Figure S2. Immunohistochemical detection of mouse mesothelin on Cryo embedded peritoneum sections. Supplementary Figure S3. Immunohistochemical detection of rat mesothelin on Cryo embedded tissue sections. Supplementary Figure S4. Immunohistochemical detection of cynomolgus monkey mesothelin on Cryo embedded tissue sections Supplementary Figure S5. Confirmation of mesothelin expression by IHC in vector or mesothelin-transfected tumor cell lines. Supplementary Figure S6. Anti-tumor activity of BAY 94-9343 in vivo.
Supplementary Fig. S3 from Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells
Authors: Tani Tetsuo , Yasuda Hiroyuki , Hamamoto Junko , Kuroda Aoi , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Miyawaki Masayoshi , Kawada Ichiro , Naoki Katsuhiko , Hayashi Yuichiro , Betsuyaku Tomoko , Soejima Kenzo
Published: April 2023

Inhibition of the EGFR pathway in H3122 parental cells
Supplementary Figure 2 from Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
Authors: Friedbichler Katrin , Hofmann Marco H. , Kroez Monika , Ostermann Elinborg , Lamche Herbert R. , Koessl Christian , Borges Eric , Pollak Michael N. , Adolf Günther , Adam Paul J.
Published: April 2023

PDF - 595KB, Correlation of rapamycin-induced AKT phosphorylation with effect of BI 836845 treatment on cell viability.
Supplementary Figure 6 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
Authors: Garcia Khristofer , Blank Jonathan L. , Bouck David C. , Liu Xiaozhen J. , Sappal Darshan S. , Hather Greg , Cosmopoulos Katherine , Thomas Michael P. , Kuranda Mike , Pickard Michael D. , Liu Ray , Bandi Syamala , Smith Peter G. , Lightcap Eric S.
Published: April 2023

PDF file - 402KB, The Combination of MLN4924 and Mitomycin C Leads to Increased DNA Strand Breaks.
Supplementary Materials and Methods from Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions
Authors: Mineharu Yohei , Kamran Neha , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Supplementary materials and methods
Supplementary Table 2 from Rationale and Preclinical Efficacy of a Novel Anti-EMP2 Antibody for the Treatment of Invasive Breast Cancer
Authors: Fu Maoyong , Maresh Erin L. , Helguera Gustavo F. , Kiyohara Meagan , Qin Yu , Ashki Negin , Daniels-Wells Tracy R. , Aziz Najib , Gordon Lynn K. , Braun Jonathan , Elshimali Yahya , Soslow Robert A. , Penichet Manuel L. , Goodglick Lee , Wadehra Madhuri
Published: April 2023

PDF - 54K, Supplementary Table 2. Clinical Data for Invasive Breast Cancer Patients used in the TMA.
Supplementary Table 1 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Authors: Wang Jing , Pursell Natalie W. , Samson Maria Elena S. , Atoyan Ruzanna , Ma Anna W. , Selmi Abdelkader , Xu Wanlu , Cai Xiong , Voi Maurizio , Savagner Pierre , Lai Cheng-Jung
Published: April 2023

PDF file - 28K, Growth inhibitory IC50s of indicated compounds in parental and erlotinib-TR HCC827 cells.
Supplementary Figure 1 from Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Authors: Wang Jing , Pursell Natalie W. , Samson Maria Elena S. , Atoyan Ruzanna , Ma Anna W. , Selmi Abdelkader , Xu Wanlu , Cai Xiong , Voi Maurizio , Savagner Pierre , Lai Cheng-Jung
Published: April 2023

PDF file - 185K, Growth inhibitory IC50s of indicated compounds in parental and erlotinib-TR HCC827 cells.
Supplementary Figure 4 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Authors: Fritsch Christine , Huang Alan , Chatenay-Rivauday Christian , Schnell Christian , Reddy Anupama , Liu Manway , Kauffmann Audrey , Guthy Daniel , Erdmann Dirk , De Pover Alain , Furet Pascal , Gao Hui , Ferretti Stephane , Wang Youzhen , Trappe Joerg , Brachmann Saskia M. , Maira Sauveur-Michel , Wilson Christopher , Boehm Markus , Garcia-Echeverria Carlos , Chene Patrick , Wiesmann Marion , Cozens Robert , Lehar Joseph , Schlegel Robert , Caravatti Giorgio , Hofmann Francesco , Sellers William R.
Published: April 2023

PDF - 60K, Linear correlation observed between tumor growth inhibition (% T/C) or tumor regression and the fraction of time over the in vivo S473P-Akt IC80 in different cancer cell line-derived tumor xenografts implanted in nude mice (represented as dots) and nude rats (represented as triangles) following NVP-BYL719 treatment (R2=0.77, p<0.001, n=27).
Supplementary Figure 2 from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Authors: Fritsch Christine , Huang Alan , Chatenay-Rivauday Christian , Schnell Christian , Reddy Anupama , Liu Manway , Kauffmann Audrey , Guthy Daniel , Erdmann Dirk , De Pover Alain , Furet Pascal , Gao Hui , Ferretti Stephane , Wang Youzhen , Trappe Joerg , Brachmann Saskia M. , Maira Sauveur-Michel , Wilson Christopher , Boehm Markus , Garcia-Echeverria Carlos , Chene Patrick , Wiesmann Marion , Cozens Robert , Lehar Joseph , Schlegel Robert , Caravatti Giorgio , Hofmann Francesco , Sellers William R.
Published: April 2023

PDF - 71K, Rat1-myr-p110alpha (blue), beta (green) or delta (red) cells were treated with increasing concentrations of NVP-BYL719 for 30 minutes. Levels of S473P-Akt in cell extracts were quantified by Reverse Phase Protein Array as described in (18) and plotted as percentage of untreated control cells. The graph illustrates n=3 independent experiments. IC50s (plus/minus) SD and IC80s (plus/minus) SD of n=3 independent experiments are reported..
Supplementary Figure 5 from Coordinate Hyperactivation of Notch1 and Ras/MAPK Pathways Correlates with Poor Patient Survival: Novel Therapeutic Strategy for Aggressive Breast Cancers
Authors: Mittal Suruchi , Sharma Ankur , Balaji Sai A. , Gowda Manju C. , Dighe Rajan R. , Kumar Rekha V. , Rangarajan Annapoorni
Published: April 2023

Supplementary Figure 5: HCC-1806 cells (1x106) were injected into nude mice and allowed to attain volume of 100-200 mm3. Control IgG, DMSO, MAb602.101 (15mg/kg b.w.), PD98059 (50microM) or combination was administered to the animals every 72 hours and tumors were excised for end point analysis.
Supplementary Figure 2 from An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype
Authors: Larocca Cecilia , Cohen Joseph R. , Fernando Romaine I. , Huang Bruce , Hamilton Duane H. , Palena Claudia
Published: April 2023

PDF file - 326K, Treatment with SD-208 reverts the mesenchymal phenotype of colon carcinoma cell lines.
Supplementary Figure 2 from Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis
Authors: Petruccelli Luca A. , Pettersson Filippa , del Rincón Sonia V. , Guilbert Cynthia , Licht Jonathan D. , Miller Wilson H.
Published: April 2023

PDF file - 3929K, PLZF-RARα enhances the effect of vorinostat on apoptosis and BCL2.
Supplementary Table 2 from BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Authors: Kutluk Cenik Bercin , Ostapoff Katherine T. , Gerber David E. , Brekken Rolf A.
Published: April 2023

PDF - 35KB, Supplemental Table showing IC50s of chemotherapy, BIBF 1120 and tbe combination in lung and pancreatic cancer cell lines.
Supplementary Figure 8 from A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Authors: Amin Karishma S. , Jagadeesh Shankar , Baishya Gakul , Rao Paruchuri G. , Barua Nabin C. , Bhattacharya Samir , Banerjee Partha P.
Published: April 2023

PDF file - 273K, Determination of the effect of mahanine on the nuclear localization and cellular levels of AR in non-tumorgenic prostate epithelial cells.
Supplementary Table 5 from Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer
Authors: Meric-Bernstam Funda , Frampton Garrett M. , Ferrer-Lozano Jaime , Yelensky Roman , Pérez-Fidalgo Jose A. , Wang Ying , Palmer Gary A. , Ross Jeffrey S. , Miller Vincent A. , Su Xiaoping , Eroles Pilar , Barrera Juan Antonio , Burgues Octavio , Lluch Ana M. , Zheng Xiaofeng , Sahin Aysegul , Stephens Philip J. , Mills Gordon B. , Cronin Maureen T. , Gonzalez-Angulo Ana M.
Published: April 2023

PDF - 42K, Selected actionable alterations in patients.
Supplementary Figure 1 from SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
Authors: Brenca Monica , Rossi Sabrina , Lorenzetto Erica , Piccinin Elena , Piccinin Sara , Rossi Francesca Maria , Giuliano Alberto , Dei Tos Angelo Paolo , Maestro Roberta , Modena Piergiorgio
Published: April 2023

Supplementary Figure 1 � PDF file 96K, G402 renal rhabdoid tumor cell line.\
Supplementary Figure 1 from Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Authors: Yu Bing , Liu Wei , Yu Wen-Mei , Loh Mignon L. , Alter Shawn , Guvench Olgun , MacKerell Alexander D. , Tang Li-Da , Qu Cheng-Kui
Published: April 2023

PDF file - 80KB, Identification of active compounds that inhibited the phosphatase activity of SHP2 with various efficiencies.
Supplementary Table 1 from Inhibition of Akt Reverses the Acquired Resistance to Sorafenib by Switching Protective Autophagy to Autophagic Cell Death in Hepatocellular Carcinoma
Authors: Zhai Bo , Hu Fengli , Jiang Xian , Xu Jun , Zhao Dali , Liu Bing , Pan Shangha , Dong Xuesong , Tan Gang , Wei Zheng , Qiao Haiquan , Jiang Hongchi , Sun Xueying
Published: April 2023

PDF file - 142K, Supplementary Table S1. Alteration of protein expression in sorafenib-resistant cells compared with parental cells in the presence or absence of sorafenib.
Supplementary Figures 1 through 6 from The Use of Olaparib (AZD2281) Potentiates SN-38 Cytotoxicity in Colon Cancer Cells by Indirect Inhibition of Rad51-Mediated Repair of DNA Double-Strand Breaks
Authors: Tahara Makiko , Inoue Takeshi , Sato Futoshi , Miyakura Yasuyuki , Horie Hisanaga , Yasuda Yoshikazu , Fujii Hirofumi , Kotake Kenjiro , Sugano Kokichi
Published: April 2023

PDF - 949K, Fig. S1: Cell counts with cell diameters in colon cancer cells. Fig. S2: Clonogenic assay. Fig. S3: Immnofluorescence double staining for BrdU and 53BP1. Fig. S4: Western blot analysis. Fig. S5: Cell counts with cell diameters in SW1116 transfected with siRNA. Fig. S6: Cell counts with cell diameters in HCT116 transfected with siRNA.
Supplementary Data 2 from Antitumor Effects in Gastrointestinal Stromal Tumors Using Photodynamic Therapy with a Novel Glucose-Conjugated Chlorin
Authors: Tanaka Mamoru , Kataoka Hiromi , Yano Shigenobu , Ohi Hiromi , Moriwaki Kazuhiro , Akashi Haruo , Taguchi Takahiro , Hayashi Noriyuki , Hamano Shingo , Mori Yoshinori , Kubota Eiji , Tanida Satoshi , Joh Takashi
Published: April 2023

PDF file - 125KB, H2TFPC-SGlc tissue concentration in mice.
Supplemental Table S1 from Angiotensin-(1-7) Decreases Cell Growth and Angiogenesis of Human Nasopharyngeal Carcinoma Xenografts
Authors: Pei Nana , Wan Renqiang , Chen Xinglu , Li Andrew , Zhang Yanling , Li Jinlong , Du Hongyan , Chen Baihong , Wei Wenjin , Qi Yanfei , Zhang Yi , Katovich Michael J. , Sumners Colin , Zheng Haifa , Li Hongwei
Published: April 2023

Supplemental Table S1. Primers for real-time RT-PCR
Supplementary Figures 1 through 6 from Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines In Vitro and In Vivo
Authors: Huang Lynn Y.L. , Chang Chia-Chi , Lee Ying-Shuan , Chang Jia-Ming , Huang Jiann-Jyh , Chuang Shih-Hsien , Kao Kuo-Jang , Lau Gillian M.G. , Tsai Pei-Yi , Liu Chia-Wei , Lin Her-Sheng , Lau Johnson Y.N.
Published: April 2023

PDF - 1333K, Figure S1. Summary of structural modifications. Figure S2. Hec1 localization. Figure S3. Activation of apoptosis. Figure S4. Subacute toxicity study: histological sections. Figure S5. Subacute toxicity study: organ weight and blood indices. Figure S6. Additional breast cancer xenograft mouse models.
Supplementary Figure 5 from MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Authors: Muñoz-Galván Sandra , Gutierrez Gabriel , Perez Marco , Carnero Amancio
Published: April 2023

Supplementary Figure S5 - MAP17 expression reduces bortezomib-induced NFKB pathway activation. Quantification of the western blots of p-p65, p65, p-IkBα and IkBα from Figure 2A.
Supplementary Table 3 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 56K, Pharmacokinetic parameters of ASP3026 after 5-day repeated oral dosing of ASP3026 in NOD/SCID mice xenografted with NCI-H2228 cells.
Supplementary Figure 2 from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma
Authors: Jiang Ning , Wang Dongsheng , Hu Zhongliang , Shin Hyung Ju C. , Qian Guoqing , Rahman Mohammad Aminur , Zhang Hongzheng , Amin A.R.M. Ruhul , Nannapaneni Sreenivas , Wang Xiaojing , Chen Zhengjia , Garcia Gabriela , MacBeath Gavin , Shin Dong M. , Khuri Fadlo R. , Ma Jun , Chen Zhuo G. , Saba Nabil F.
Published: April 2023

PDF file - 255KB, Western blot analyses of HNSCC cell lines.
Supplementary Figure 4 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 457K, Growth of H2228-luc cells in livers after inoculation into the portal vein of NOD/SCID mice.
Supplementary Figure 3 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 445K, Growth of H2228-luc cells directly inoculated into the pleural cavity of NOD/SCID mice.
Supplementary Figure 1 from The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Authors: Mori Masamichi , Ueno Yoko , Konagai Satoshi , Fushiki Hiroshi , Shimada Itsuro , Kondoh Yutaka , Saito Rika , Mori Kenichi , Shindou Nobuaki , Soga Takatoshi , Sakagami Hideki , Furutani Takashi , Doihara Hitoshi , Kudoh Masafumi , Kuromitsu Sadao
Published: April 2023

PDF file - 69K, Antitumor activity of twice-daily oral dosing of ASP3026 at 100 mg/kg in a NCI-H2228 xenograft model.
Supplementary Table 1 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 48K, Serum chemistry in FaDu metastatic spleen study mice 3 days post-treatment.
Supplementary Figures S1-S3 from Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth
Authors: Gritsina Galina , Xiao Fang , O'Brien Shane W. , Gabbasov Rashid , Maglaty Marisa A. , Xu Ren-Huan , Thapa Roshan J. , Zhou Yan , Nicolas Emmanuelle , Litwin Samuel , Balachandran Siddharth , Sigal Luis J. , Huszar Dennis , Connolly Denise C.
Published: April 2023

Supplementary Figures S1-S3: Supplementary Figure S1. AZD1480 abrogates STAT3 DNA binding while targeting JAK2 or STAT3 has little effect on viability or proliferation in cultured cells. Supplementary Figure S2. Pharmacodynamics of AZD1480 treatment. Supplementary Figure S3. Flow cytometry analysis of immune cell subpopulations in tumors and peritoneal washes from vehicle- and AZD1480-treated mice.
Supplementary Figure 2 from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 1588K, Weight change in mice for SCC-15, UM-11b and FaDu xenograft flank tumor models of HNSCC following treatment with s50-TBG-RNAi-CK2.
Supplementary Figures 1 - 8 from Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
Authors: Xu Shili , Grande Fedora , Garofalo Antonio , Neamati Nouri
Published: April 2023

PDF file - 1250K, Supplementary Figure S1: SC144 exhibits cytotoxicity in human ovarian cancer cell lines; Supplementary Figure S2: Confirmation of gp130 protein expression, glycosylation phosphorylation and internalization; Supplementary Figure S3: Constitutive Stat3 (Tyr705) phosphorylation is gp130 dependent; Supplementary Figure S4: gp130/Stat3 knockdown suppresses the expression of downstream genes; Supplementary Figure S5: SC144's effects on pancreatic cancer cells; Supplementary Figure S6: Gp130/Stat3 inhibition causes cytotoxicity in ovarian cancer cells; Supplementary Figure S7: SC144 inhibits cytokine-induced Stat3 activation; Supplementary Figure S8: SC144 treatment did not cause systemic toxicity.
Supplementary Figure 3 from Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside–Nucleoside Analogue Radiosensitization
Authors: Magin Simon , Papaioannou Maria , Saha Janapriya , Staudt Christian , Iliakis George
Published: April 2023

Supplementary Figure 3. AraA induces DNA-replication-associated phosphorylation of H2AX in non-irradiated A549 cells
Supplementary Figure S1 from Enhancement of the Proapoptotic Properties of Newcastle Disease Virus Promotes Tumor Remission in Syngeneic Murine Cancer Models
Authors: Cuadrado-Castano Sara , Ayllon Juan , Mansour Mena , de la Iglesia-Vicente Janis , Jordan Stefan , Tripathi Shashank , García-Sastre Adolfo , Villar Enrique
Published: April 2023

PBS treated tumors: histopathology and virus immunostaining
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Figure 2A. HPLC chromatogram of tritium labeled leelamine synthesized by bromination, followed by replacement of the bromine atom with tritium. S2B. Efficacy of tritiated leelamine for killing UACC 903 melanoma cells was compared to leelamine using the MTS assay.
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Table S1. Animal survival after the intravenous administration of 30 mg/Kg body weight leelamine (DMSO) and liposomal leelamine (Saline). Number of surviving animals or changes in hemolysis and vascular coagulation (n=3).
Data Supplement from Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Sharma Arati , Kuzu Omer F. , Robertson Gavin P.
Published: April 2023

Supplemental Table S3. Efficacy of Nanolipolee-007 for killing wild type B-RAF containing melanoma cell lines SbCl2, C8161.Cl9 and MelJuSo was examined by MTS assay and found to have IC50s ranging from 7-8 μmol/L compared to cell lines that contained V600EB-RAF (SK-Mel-24, 1205 Lu, UACC 903), having IC50s of 2-2.3 µmol/L.
Supplementary Figure 4 from NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Authors: Yoshida Yasuyuki , Ozawa Tomoko , Yao Tsun-Wen , Shen Wang , Brown Dennis , Parsa Andrew T. , Raizer Jeffrey J. , Cheng Shi-Yuan , Stegh Alexander H. , Mazar Andrew P. , Giles Francis J. , Sarkaria Jann N. , Butowski Nicholas , Nicolaides Theodore , James C. David
Published: April 2023

Supplementary Figure 4: Plasma PK results associated with oral administration of 5 mg/kg NT113 in rats.
Supplementary Material from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Authors: Symolon Holly , Bushnev Anatoliy , Peng Qiong , Ramaraju Harsha , Mays Suzanne G. , Allegood Jeremy C. , Pruett Sarah T. , Sullards M. Cameron , Dillehay Dirck L. , Liotta Dennis C. , Merrill Alfred H.
Published: April 2023

Supplementary Material from Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Supplementary Table S2 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

List of primers and PCR conditions.
Supplementary Figure 5 from Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Authors: Zahonero Cristina , Aguilera Pilar , Ramírez-Castillejo Carmen , Pajares Marta , Bolós Maria Victoria , Cantero Diana , Perez-Nuñez Angel , Hernández-Laín Aurelio , Sánchez-Gómez Pilar , Sepúlveda Juan Manuel
Published: April 2023

Analysis of differentiation genes after long term dacomitinib treatment.
Supplemental Figure S3 from Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species–Dependent Targeting of Specificity Protein Transcription Factors
Authors: Hedrick Erik , Crose Lisa , Linardic Corinne M. , Safe Stephen
Published: April 2023

Supplemental Figure S3. Tumor lysates from control and panobinostat-treated mice were analyzed by western blots.
Supplementary Figure Legend from Pseudogene PTENP1 Functions as a Competing Endogenous RNA to Suppress Clear-Cell Renal Cell Carcinoma Progression
Authors: Yu Gan , Yao Weimin , Gumireddy Kiranmai , Li Anping , Wang Ji , Xiao Wei , Chen Ke , Xiao Haibing , Li Heng , Tang Kun , Ye Zhangqun , Huang Qihong , Xu Hua
Published: April 2023

Supplementary Figure Legend
Supplementary Figure S11 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma
Authors: Kong Li Ren , Chua Kian Ngiap , Sim Wen Jing , Ng Hsien Chun , Bi Chonglei , Ho Jingshan , Nga Min En , Pang Yin Huei , Ong Weijie Richard , Soo Ross Andrew , Huynh Hung , Chng Wee Joo , Thiery Jean-Paul , Goh Boon Cher
Published: April 2023

MEK inhibition triggers G1 arrest, while cisplatin induced S-phase arrest, in lung SCC cells.
Supplementary Figure 4 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Figure 4 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplementary Figure 1 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Authors: Yang Bin-Xia , Duan Yong-Juan , Dong Cheng-Ya , Zhang Fang , Gao Wei-Feng , Cui Xue-Ying , Lin Yong-Min , Ma Xiao-Tong
Published: April 2023

Supplementary Figure 1 from Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Supplmental Figure 1 from miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma
Authors: Zhang Manchao , Piao Longzhu , Datta Jharna , Lang James C. , Xie Xiujie , Teknos Theodoros N. , Mapp Anna K. , Pan Quintin
Published: April 2023

Supplemental Figure 1. Restoration of miR-124 in CAL27 enhances the anti-tumor efficacy of afatinib.
Supplemental Figure Legend from miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma
Authors: Zhang Manchao , Piao Longzhu , Datta Jharna , Lang James C. , Xie Xiujie , Teknos Theodoros N. , Mapp Anna K. , Pan Quintin
Published: April 2023

Supplemental Figure Legend
Supplementary Figure S2 from AMG 595, an Anti-EGFRvIII Antibody–Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
Authors: Hamblett Kevin J. , Kozlosky Carl J. , Siu Sophia , Chang Wesley S. , Liu Hua , Foltz Ian N. , Trueblood Esther S. , Meininger David , Arora Taruna , Twomey Brian , Vonderfecht Steven L. , Chen Qing , Hill John S. , Fanslow William C.
Published: April 2023

Supplementary Figure S2. Cell Growth inhibition in A431 cells (wild-type EGFR overexpressing cells)
Data Supplement from An In Vivo Antilymphatic Screen in Zebrafish Identifies Novel Inhibitors of Mammalian Lymphangiogenesis and Lymphatic-Mediated Metastasis
Authors: Astin Jonathan W. , Jamieson Stephen M.F. , Eng Tiffany C.Y. , Flores Maria V. , Misa June P. , Chien Annie , Crosier Kathryn E. , Crosier Philip S.
Published: April 2023

Video S4. Confocal time-lapse imaging of a lyve1:egfp embryo from 30 hpf to 49:52 hpf (19:52h) treated with 5 μM flunarizine. Time-lapse image z-stacks were collected 10 min apart; movie was made at 7 frames per second.
Supplementary Table 2 from Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts
Authors: Paulitschke Verena , Berger Walter , Paulitschke Philipp , Hofstätter Elisabeth , Knapp Bernhard , Dingelmaier-Hovorka Ruth , Födinger Dagmar , Jäger Walter , Szekeres Thomas , Meshcheryakova Anastasia , Bileck Andrea , Pirker Christine , Pehamberger Hubert , Gerner Christopher , Kunstfeld Rainer
Published: April 2023

Comparison of protein expression in A375 and M24met by 2D-gel electrophoresis. Corresponding proteins which are assigned in the 2-D gel in Figure 2. Accession numbers are from the Uniprot database. Vol indicates the volume identified by 2D-gel electrophoresis n.d =not determined
Supplementary Figures 1-4 from Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity
Authors: D'Angelo Rosemarie C. , Ouzounova Maria , Davis April , Choi Daejin , Tchuenkam Stevie M. , Kim Gwangil , Luther Tahra , Quraishi Ahmed A. , Senbabaoglu Yasin , Conley Sarah J. , Clouthier Shawn G. , Hassan Khaled A. , Wicha Max S. , Korkaya Hasan
Published: April 2023

Supplemental Figure 1. Notch4 mRNA expression correlates with Notch ligands and downstream effectors; Supplemental Figure 2. A schematic outline of experimental procedures; Supplemental Figure 3. A single Notch+ cell has the capacity to generate tumors that represents the initial heterogeneity; Supplemental Figure 4. Evaluation of tumor growth following the treatment of animals with GSI, Docetaxel or combination treatments.
Supplementary Figure 1 from Rho Kinase Inhibitor Fasudil Suppresses the Vasculogenic Mimicry of B16 Mouse Melanoma Cells Both In Vitro and In Vivo
Authors: Xia Yun , Cai Xian-Yi , Fan Ji-Quan , Zhang Li-Ling , Ren Jing-Hua , Chen Jing , Li Zhen-Yu , Zhang Rui-Guang , Zhu Fang , Wu Gang
Published: April 2023

B16 cells were seeded in 96-well plates and incubated with various concentrations of fasudil for 24h. The cell inhibitory rate was measured using an MTT assay. Fasudil inhibited B16 cell proliferation in a dose-dependent manner, and the IC50 for 24h of fasudil in B16 cells was 71 {plus minus} 5.8Î¼M.
Data Supplement from The CREB-Binding Protein Inhibitor ICG-001 Suppresses Pancreatic Cancer Growth
Authors: Arensman Michael D. , Telesca Donatello , Lay Anna R. , Kershaw Kathleen M. , Wu Nanping , Donahue Timothy R. , Dawson David W.
Published: April 2023

Supplemental Figure 1. ICG-001 dose response curves for IC50 calculations.
Supplementary Figure Legends from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file provides the legends to Supplementary figures 1-6.
Supplementary Figure 5 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows the aerobic and anoxic toxicity of AZD3965.
Supplementary Figure 3 from Inhibition of Monocarboxylate Transporter-1 (MCT1) by AZD3965 Enhances Radiosensitivity by Reducing Lactate Transport
Authors: Bola Becky M. , Chadwick Amy L. , Michopoulos Filippos , Blount Kathryn G. , Telfer Brian A. , Williams Kaye J. , Smith Paul D. , Critchlow Susan E. , Stratford Ian J.
Published: April 2023

This file shows a comparison of the effect of hypoxia on metabolite profiles.
Data Supplement from Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells
Authors: Munoz Jessian L. , Rodriguez-Cruz Vivian , Greco Steven J. , Nagula Vipul , Scotto Kathleen W. , Rameshwar Pranela
Published: April 2023

Figure S1. The band densities for the western blot for P-gp in Fig. 1D were normalized to β-actin. The data are presented as fold expression for both cell lines, three different experiments. Figure S2. The band densities for cJun/Fos and p-cJun/Fos in the western blots with U87 extracts in Fig. 4B were normalized to β-actin and then presented as Fold Expression, three different experiments. Figure S3. The band densities for cJun/Fos and p-cJun/Fos in the western blots with T98G extracts in Fig. 4B were normalized to β-actin and then presented as Fold Expression, three different experiments. Figure S4. Bands shown for the western blots for P-gp in Fig. 5C were normalized band with the bands for β-actin. The results are expressed as fold expression, three different experiments.
Data Supplement from Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
Authors: Custodio Ana , Moreno-Rubio Juan , Aparicio Jorge , Gallego-Plazas Javier , Yaya Ricardo , Maurel Joan , Rodríguez-Salas Nuria , Burgos Emilio , Ramos David , Calatrava Ana , Andrada Encarna , Díaz-López Esther , Sánchez Antonio , Madero Rosario , Cejas Paloma , Feliu Jaime
Published: April 2023

Supplementary Table S2. Cox regression multivariate analysis for overall survival (OS) in the training and validation cohorts.
Supplementary Figure S1 from Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1
Authors: Castilla Carolina , Flores M. Luz , Medina Rafael , Pérez-Valderrama Begoña , Romero Francisco , Tortolero María , Japón Miguel A. , Sáez Carmen
Published: April 2023

Supplementary Figure S1: A, LNCaP cells were silenced with PTTG1 siRNA or with a non-targeting control siRNA and treated with 2.5 microM paclitaxel during 24 and 48 h. B, LNCaP cells were transiently transfected with a plasmid carrying a non degradable PTTG1 mutant (pEF/Securin KAA-DM) or with empty vector and treated with 2.5 microM paclitaxel during 48 h. C, PC3 cells were silenced with PTTG1 siRNA or with a non-targeting control siRNA and treated with 2.5 microM paclitaxel during 24 and 48 h. D, PC3 cells were transiently transfected with a plasmid carrying a non degradable PTTG1 mutant (pEF/Securin KAA-DM) or with empty vector and treated with 2.5 microM paclitaxel during 48 h. E, PC3 and PC3 PTXR cells were treated with 2.5 microM paclitaxel during 48 h. In all cases, representative photographs of a FISH for chromosomes 8 and 17 are shown.
Supplementary Table S3 from Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin–Deficient Cells
Authors: Telford Bryony J. , Chen Augustine , Beetham Henry , Frick James , Brew Tom P. , Gould Cathryn M. , Single Andrew , Godwin Tanis , Simpson Kaylene J. , Guilford Parry
Published: April 2023

Supplementary Table S3. List SL2. Candidates meeting the more stringent criteria of {less than or equal to}85% death in MCF10A and {greater than or equal to} 15% increased death in CDH1-/- cells compared to MCF10A cells.
Supplemental Figure 1,Supplemental Figure 2,Supplemental Figure 3, Supplemental Figure 4 from Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Authors: Sugano Teppei , Seike Masahiro , Noro Rintaro , Soeno Chie , Chiba Mika , Zou Fenfei , Nakamichi Shinji , Nishijima Nobuhiko , Matsumoto Masaru , Miyanaga Akihiko , Kubota Kaoru , Gemma Akihiko
Published: April 2023

Supplemental Figure 1:Protein levels of p-MET, MET and ABCB1 were examined in 7 SQ cell lines by Western blot analysis Supplemental Figure 2: FGFR inhibition overcomes the resistance to PHA-665752 in EBC-1R cells Supplemental Figure 3: ABCB1 overexpression in cloned EBC-1R cells Supplemental Figure 4: Immunohistochemical staining for ABCB1 protein expression in tumor cells from SQ patients
Supplementary Figure 3 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 3. Recruitment of hnRNPA1 and hnRNPA2 to splice sites for AR variants other than AR-V7
Supplementary Figure 1 from NF-κB2/p52:c-Myc:hnRNPA1 Pathway Regulates Expression of Androgen Receptor Splice Variants and Enzalutamide Sensitivity in Prostate Cancer
Authors: Nadiminty Nagalakshmi , Tummala Ramakumar , Liu Chengfei , Lou Wei , Evans Christopher P. , Gao Allen C.
Published: April 2023

Supplementary Figure 1. Schematic representation of hnRNPA1 and hnRNAP2 binding sites in AR pre-mRNA
Supplementary Materials and Methods from Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance
Authors: Pedersen Mikkel W. , Jacobsen Helle J. , Koefoed Klaus , Dahlman Anna , Kjær Ida , Poulsen Thomas T. , Meijer Per-Johan , Nielsen Lars S. , Horak Ivan D. , Lantto Johan , Kragh Michael
Published: April 2023

Short description of methods and materials used for supplemmentary figures. BioLayer Interferometry, ADCC and CDC assays.
Supplemental Figure 1 from CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis
Authors: Burgos-Ojeda Daniela , Wu Rong , McLean Karen , Chen Yu-Chih , Talpaz Moshe , Yoon Euisik , Cho Kathleen R. , Buckanovich Ronald J.
Published: April 2023

Supplemental Figure 1. Bioluminescent images of cancer stem cell markers evaluated
Supplementary Figure S2 from Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth
Authors: Ramirez Yulian P. , Mladek Ann C. , Phillips Roger M. , Gynther Mikko , Rautio Jarkko , Ross Alonzo H. , Wheelhouse Richard T. , Sakaria Jann N.
Published: April 2023

Supplementary Figure S2. Summary of prodrug activation. Summary of prodrug activation and drug mechanisms of action for TMZ, DP68 and DP86 highlighting the roles of diazonium and aziridinium ion intermediates. (A-B) TMZ hydrolysis, generation of methyldiazonium ions and reaction with DNA; (C) DP86 monoalkylation; (D) DP68 crosslink formation.
Supplementary Figure 4 from Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
Authors: Alewine Christine , Xiang Laiman , Yamori Takao , Niederfellner Gerhard , Bosslet Klaus , Pastan Ira
Published: April 2023

Supplementary Figure 4. Shows cell killing with combination paclitaxel and RG7787 in vitro
Supplementary Figures S1-S7 from Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Authors: Huang Qingling , Schneeberger Valentina E. , Luetteke Noreen , Jin Chengliu , Afzal Roha , Budzevich Mikalai M. , Makanji Rikesh J. , Martinez Gary V. , Shen Tao , Zhao Lichao , Fung Kar-Ming , Haura Eric B. , Coppola Domenico , Wu Jie
Published: April 2023

SFigure 1: Histological examination of mouse lungs; SFigure 2: Tissue sections from human lung adenocarcinoma; SFigure 3: Cabozantinib (CBT) and vandetanib (VDT) resistant cells; SFigure 4: Comparison of in vitro inhibition of RET, RETV804L and RETV804M by ponatinib, cabozantinib, vandetanib, and lenvatinib; SFigure 5: Ponatinib treatment schedule and body weight measurements; SFigure 6: Lung section histology from Dox-induced C/KR mice and treated with vehicle or ponatinib for 1 months; SFigure 7: μCT examination of dox-induced C/KR mice with lung tumors before and after one month treatment with vehicle or ponatinib.
Supplementary Information from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Information
Supplementary Figure 3 from Combining Onartuzumab with Erlotinib Inhibits Growth of Non–Small Cell Lung Cancer with Activating EGFR Mutations and HGF Overexpression
Authors: Sano Yuji , Hashimoto Eri , Nakatani Noriaki , Abe Masaichi , Satoh Yasuko , Sakata Kiyoaki , Fujii Toshihiko , Fujimoto-Ouchi Kaori , Sugimoto Masamichi , Nagahashi Shigehisa , Aoki Masahiro , Motegi Hiroshi , Sasaki Eiichi , Yatabe Yasushi
Published: April 2023

Supplementary Figure 3. In vivo efficacy of onartuzumab combined with erlotinib in tumors harboring an activating EGFR mutation and with a high level of HGF expression.
Supplementary Figure S5 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S5 provides data on cell death induction of scTRAIL fusion proteins on Colo205 cells in the presence of blocking antibody.
Supplementary Figure S3 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S3 provides data on cell death induction of scTRAIL fusion proteins
Supplementary Figure S1 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
Authors: Hutt Meike , Marquardt Lisa , Seifert Oliver , Siegemund Martin , Müller Ines , Kulms Dagmar , Pfizenmaier Klaus , Kontermann Roland E.
Published: April 2023

Figure S1 provides data on the biochemical characterization of scTRAIL fusion proteins.
Supplementary Figure S5 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Effects of GSK3beta inhibition on the formation of invadopodium-like microstructures and matrix degradation by U251 cells.
Supplementary Figure S1 from Glycogen Synthase Kinase 3β Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway
Authors: Chikano Yuri , Domoto Takahiro , Furuta Takuya , Sabit Hemragul , Kitano-Tamura Ayako , Pyko Ilya V. , Takino Takahisa , Sai Yoshimichi , Hayashi Yutaka , Sato Hiroshi , Miyamoto Ken-ichi , Nakada Mitsutoshi , Minamoto Toshinari
Published: April 2023

Effect of GSK3beta RNA interference on migration and invasion of glioblastoma cells.